ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside

Tyrosine Kinase Inhibitors (TKI) have significantly changed the landscape of current cancer therapy. Understanding of mechanisms of aberrant TK signaling and strategies to inhibit TKs in cancer, further promote the development of novel agents. ABT-869, a novel ATP-competitive receptor tyrosine kinas...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jianbiao, Goh, Boon-Cher, Albert, Daniel H, Chen, Chien-Shing
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2729745/
https://www.ncbi.nlm.nih.gov/pubmed/19642998
http://dx.doi.org/10.1186/1756-8722-2-33

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2729745/
https://www.ncbi.nlm.nih.gov/pubmed/19642998
http://dx.doi.org/10.1186/1756-8722-2-33

Ejemplares similares